BM 201Alternative Names: BM201
Latest Information Update: 24 Jan 2017
At a glance
- Originator BioMarin Pharmaceutical
- Class Peptide hydrolases
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Burns
Most Recent Events
- 23 Jan 2017 Discontinued - Preclinical for Burns in USA (unspecified route)
- 31 Oct 2000 Suspended-Preclinical for Burns in USA (Unknown route)